Hints and tips:
Related Special Reports
...In a statement, Sandoz called AbbVie’s continued dominance “the epitome of a dysfunctional market”....
...The Swiss pharmaceuticals group is following many rivals to focus its operations on higher-value innovative treatments rather than the cheaper off-patent drugs made by Sandoz, including generic versions...
...Founded by the Sandoz family, the business merged with Ciba-Geigy to create Novartis in 1996....
...The case for splitting off Sandoz is not conclusive. A push by Narasimhan to make Sandoz’s manufacturing and other operations independent of Novartis is nearly complete....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...“Africa is a key market for Sputnik V,” said the Russian Direct Investment Fund, a Kremlin-run wealth fund overseeing Sputnik V’s foreign sales....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...at Taro Pharmaceuticals....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...To boost supplies of antimalarials, generics manufacturers Teva and Novartis’ Sandoz have pledged to donate millions of doses to US hospitals....
...If there is a sense from this earnings season that confidence in a V-shaped recovery for profits is misplaced, then the impact will probably be hardest on companies with weak balance sheets, and on those...
...Beyond these three biotechs, Crispr could end up transforming the entire pharmaceutical industry....
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
...However, in an interview with the Financial Times late last year, Mr Narasimhan insisted there was no plan to spin off Sandoz. “We’re committed to Sandoz....
...Rivals entering the market include Amgen, Sandoz, Biogen, Samsung Bioepis and Mylan. In the first quarter, Humira represented 56 per cent of revenue at $4.4bn....
...We wind up teaming up with American Eagle, and I sell part of my business to American Eagle. And I got Urban Necessities inside American Eagle....
...On Thursday, Novartis said it would sell portions of the Sandoz US portfolio to Aurobindo Pharma USA in order to focus on “higher growth areas”....
...patent that for 15 years has protected Humira, the world’s best-selling prescription drug, from generic competition expires in Europe — triggering a tussle among a string of the most prominent names in the pharmaceuticals...
...Amgen, Sandoz, Mylan, and Samsung Bioepis launched copycat drugs in Europe two weeks ago. Prices differ between markets but are between 10 and 80 per cent cheaper....
...Yet rather than continuing to use Sandoz’s biosimilar, the Marsden has now chosen one manufactured by privately owned Napp Pharmaceuticals, which brought the first Rituximab copycat to market last year....
...She worked as a janitorial supervisor at C&W client Lonza, a Swiss pharmaceuticals group, which has a production facility in Portsmouth, New Hampshire....
...He places human embryonic and pluripotent stem cells — that have the potential to grow into nearly every cell of the body — in tiny ‘U’ or ‘V’ shaped dishes in the lab to grow them into different types of...
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
...Reddy’s Laboratories, Inc.; Emcure Pharmaceuticals, Ltd.; Glenmark Pharmaceuticals, Inc.; Lannett Company, Inc.; Par Pharmaceutical Companies, Inc.; Sandoz, Inc.; Sun Pharmaceutical Industries,Inc.; and...
...To its supporters, the decision to approve the inclusion of silicon and software as part of a pharmaceutical product heralds a new era....
International Edition